Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Pacira BioSciences (PCRX)

Pacira BioSciences signs $300 million revolving credit facility, repays term loan

Neutral Impact 3 of 5 financing Written later

On July 3, 2025, Pacira BioSciences entered into a new credit agreement with Wells Fargo as administrative agent, providing a $300.0 million senior secured revolving facility maturing July 3, 2030. The company used part of the revolving loans to repay and terminate its existing term loan A credit agreement, with no prepayment penalties or fees reported. The filing is a refinancing and working capital arrangement, with no change to reported earnings or guidance.

Key points

  • Revolving credit facility with aggregate commitment of $300.0 million, maturing July 3, 2030
  • Secured by substantially all assets of the company and subsidiary guarantors
  • Existing term loan A credit agreement from March 31, 2023 repaid and terminated, with no prepayment penalties or fees
  • Interest spreads of 1.50% to 2.25% (base rate) and 2.50% to 3.25% (term SOFR), tied to senior secured net leverage

The filing

CompanyPacira BioSciences (PCRX)
Form8-K, current report
Filed with the SECJul 7, 2025, 8:00 AM ET
Accession number0001104659-25-065979

Items reported: 1.01 Material Definitive Agreement1.02 Termination of Material Agreement2.03 New Direct Financial Obligation

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 6:58 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 07, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.